Analyst Ratings For CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT)
Today, SunTrust Banks lowered its price target on CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT) to per share.
Some recent analyst ratings include
- 4/5/2018-HC Wainwright Reiterated Rating of Buy .
- 2/8/2018-Roth Capital initiated coverage with a Buy rating.
- 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
- 8/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
Recent Insider Trading Activity For CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT)
CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT) has insider ownership of 13.90% and institutional ownership of 39.49%.
- On 4/8/2015 Daniel L Kisner, Director, bought 4,000 with an average share price of $5.75 per share and the total transaction amounting to $23,000.00.
- On 7/30/2013 David F Hale, Director, bought 2,588 with an average share price of $11.00 per share and the total transaction amounting to $28,468.00.
- On 7/30/2013 Luke Evnin, Major Shareholder, bought 165,265 with an average share price of $11.00 per share and the total transaction amounting to $1,817,915.00.
- On 7/30/2013 Steven J Mento, CEO, bought 13,800 with an average share price of $11.00 per share and the total transaction amounting to $151,800.00.
Recent Trading Activity for CNAT – Conatus Pharmaceuticals (NASDAQ:CNAT)
Shares of CNAT – Conatus Pharmaceuticals closed the previous trading session at 4.37 down -1.64 27.29% with 4.440000057220459 shares trading hands.